Skip to main content

A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74

Terminated · Phase 1 · NCT06597656

Conditions: Duchenne Muscular Dystrophy

At a glance

Research payments reported, 2025
$316,848
U.S. investigators named
3
Sites paid
5
Planned or actual enrollment
3

About the trial

Sponsor
Sarepta Therapeutics, Inc.
Tested
delandistrogene moxeparvovec (genetic), Plasmapheresis (procedure)
Dates
Started 2024-09-18; completion 2025-08-05
Results posted
Not yet

This is a gene transfer therapy study evaluating the safety of and delandistrogene moxeparvovec dystrophin protein expression from delandistrogene moxeparvovec following therapeutic plasma exchange (plasmapheresis) in ambulatory male participants with DMD and pre-existing antibodies to AAVrh74 over a period of 59 weeks.

From ClinicalTrials.gov, last updated 2025-09-04. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sarepta Therapeutics, Inc. reported $316,848 in research payments for this study in 2025 (304 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Washington University $184,068
  • Children's Research Institute $62,210
  • Washington University in St. Louis $46,348
  • University of Florida $24,175
  • The Research Institute at Nationwide Children's Hospital $48

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.